Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

QuadMed names new president

QuadMed, a provider of onsite, near site and shared site employer-sponsored health and wellness solutions, has announced the appointment of Sue Buettner as the new president, succeeding Tim Dickman.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

Fluke Biomedical unveils new electrical safety analyzer

Fluke Biomedical, a manufacturer of biomedical test equipment and simulation products, has unveiled the ESA609 electrical safety analyzer, a new addition to its Electrical Safety portfolio.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

Medytox Solutions annual net income up

Medytox Solutions, Inc., a provider of clinical laboratory blood and urine testing services, has reported that net income attributable to the common shareholders of the company for the year ended December 31, 2013 was $5.66 million, or $0.19 per share, compared to $2.3 million, or $0.07 per share, for the year ended December 31, 2012.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

ProCannas to open three new sales offices in Florida, Canada and Mexico

Polaris International Holdings, Inc. has announced that its medical division, ProCannas, a manufacturer of pharmaceutical grade cannabinoid based products, is opening three new sales offices in Tampa, Florida; Vancouver, British Columbia, Canada; and Mexico City, Mexico in summer 2014.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

GlaxoSmithKline receives FDA approval for diabetes drug

GlaxoSmithKline plc has received FDA approval for Tanzeum as subcutaneous injection, indicated as a once-weekly treatment for type 2 diabetes.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

Epizyme receives new US patent for treatment of EZH2 cancers

Epizyme, Inc., a biopharmaceutical company, has announced that the US Patent and Trademark Office has granted US Patent No. 8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

Bristol-Myers announces encouraging results from Phase III hepatitis C study

Bristol-Myers Squibb Company has announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir, or DCV, a NS5A inhibitor, and asunaprevir, or ASV, a NS3 inhibitor, among genotype 1b hepatitis C virus, or HCV, infected patients.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

Santen's Phase III eye disorder study meets primary endpoint

Santen Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., has announced that SAKURA, or Study Assessing double-masKed Uveitis tReAtment, Study 1, the first of two Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis, or NI-PSU, has met its primary endpoint.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

Prosonix enters into licensing agreement with Mylan

Prosonix, a specialty pharmaceutical company, has entered into a global licensing agreement with Mylan Inc., a provider of generic pharmaceuticals, for Prosonix's inhaled respiratory products, PSX1001 and PSX1050.

Published By MarketLine
16 Apr 2014
NewsWire
NewsWire

Aurinia Pharmaceuticals annual net loss down

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, has reported that net loss for the year ended December 31, 2013 was C$2.71 million, or C$0.43 loss per share, compared to a net loss of C$9.69 million, or C$2.73 loss per share, for the year ended December 31, 2012.

Published By MarketLine
16 Apr 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.